Evidence map›Paper›PMID 32641651›Full record

ArticleInternal medicine (Tokyo, Japan)2020

The Impact of Hemodialysis and Liver Cirrhosis on the Plasma Concentrations of Tyrosine Kinase Inhibitors in a Patient with Chronic Myeloid Leukemia.

Yasuhiro Taniguchi, Naoto Takahashi, Masatomo Miura, Chikara Hirase, Sanae Sueda, Jorge Luis Espinoza, Shinya Rai, Shoko Nakayama, Kentaro Serizawa, Takahiro Kumode and 4 more

Open access · diamondAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Internal medicine (Tokyo, Japan), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.4field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 4 institutions in 1 country.

Yasuhiro TaniguchiDepartments of Hematology and Rheumatology, Faculty of Medicine, Kindai University Hospital, Japan.
Naoto TakahashiDepartments of Hematology, Nephrology, and Rheumatology, Akita University Graduate School of Medicine, Japan.
Masatomo MiuraDepartment of Pharmacy, Akita University Hospital, Japan.
Chikara HiraseDepartments of Hematology and Rheumatology, Faculty of Medicine, Kindai University Hospital, Japan.
Sanae SuedaDepartment of Hematology, PL General Hospital, Japan.
Jorge Luis EspinozaFaculty of Health Sciences, Institute of Medical, Pharmaceutical and Health Sciences, Kanazawa University, Japan.
Shinya RaiDepartments of Hematology and Rheumatology, Faculty of Medicine, Kindai University Hospital, Japan.
Shoko NakayamaDepartments of Hematology and Rheumatology, Faculty of Medicine, Kindai University Hospital, Japan.
Kentaro SerizawaDepartments of Hematology and Rheumatology, Faculty of Medicine, Kindai University Hospital, Japan.
Takahiro KumodeDepartments of Hematology and Rheumatology, Faculty of Medicine, Kindai University Hospital, Japan.
Yosaku WatataniDepartments of Hematology and Rheumatology, Faculty of Medicine, Kindai University Hospital, Japan.
Yasuyoshi MoritaDepartments of Hematology and Rheumatology, Faculty of Medicine, Kindai University Hospital, Japan.
Hirokazu TanakaDepartments of Hematology and Rheumatology, Faculty of Medicine, Kindai University Hospital, Japan.
Itaru MatsumuraDepartments of Hematology and Rheumatology, Faculty of Medicine, Kindai University Hospital, Japan.
Kindai University Hospital · JPAkita University · JPAkita University Hospital · JPKanazawa University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We recently treated a chronic myeloid leukemia (CML) patient with liver and renal dysfunction, who was undergoing hemodialysis (HD). He was treated with 50 mg dasatinib (DAS) once daily just before HD. The maximum plasma concentration of DAS was 227 ng/mL on a non-HD day and 46.9 ng/mL on a HD day. He was subsequently treated with 200 mg bosutinib (BOS) once daily. The plasma concentration of BOS changed from 74.5 ng/mL before HD to 58.8 ng/mL after HD. Our results indicate that close monitoring of the plasma tyrosine kinase inhibitor concentrations should be considered in CML patients with organ impairment.

Indexed as

AdultAgedAged, 80 and overAniline CompoundsAntineoplastic AgentsDasatinibFemaleHumansJapanLeukemia, Myelogenous, Chronic, BCR-ABL PositiveLiver CirrhosisMaleMiddle AgedNitrilesProtein Kinase InhibitorsQuinolinesAniline CompoundsAntineoplastic AgentsbosutinibDasatinibNitrilesProtein Kinase InhibitorsQuinolinesbosutinibdasatinibhemodialysisliver cirrhosisplasma concentrations

Identifiers

PMID32641651
PMCPMC7691019
OpenAlexW3038678212

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.